Oncodoc
@anthonymjoshua.bsky.social
Reposted by Oncodoc
🔗 : ascopubs.org/doi/10.1200/...
🙏 for the wonderful collaboration and mentorship from many experts around the globe!
@anthonymjoshua.bsky.social @oncocook.bsky.social @weldeiry.bsky.social @sarahblagden.bsky.social @viveksubbiah.bsky.social
@oncoalert.bsky.social @oncodaily.bsky.social
🙏 for the wonderful collaboration and mentorship from many experts around the globe!
@anthonymjoshua.bsky.social @oncocook.bsky.social @weldeiry.bsky.social @sarahblagden.bsky.social @viveksubbiah.bsky.social
@oncoalert.bsky.social @oncodaily.bsky.social
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
PURPOSEOver the past 15 years, the landscape of early phase clinical trials (EPCTs) has undergone
a remarkable expansion in both quantity and intricacy. The proliferation of sites,
trials, sponsors, a...
ascopubs.org
January 15, 2025 at 5:58 PM
🔗 : ascopubs.org/doi/10.1200/...
🙏 for the wonderful collaboration and mentorship from many experts around the globe!
@anthonymjoshua.bsky.social @oncocook.bsky.social @weldeiry.bsky.social @sarahblagden.bsky.social @viveksubbiah.bsky.social
@oncoalert.bsky.social @oncodaily.bsky.social
🙏 for the wonderful collaboration and mentorship from many experts around the globe!
@anthonymjoshua.bsky.social @oncocook.bsky.social @weldeiry.bsky.social @sarahblagden.bsky.social @viveksubbiah.bsky.social
@oncoalert.bsky.social @oncodaily.bsky.social
Reposted by Oncodoc
Since #EMBARK data there is a need to define high risk #BCR #ProstateCancer
Best data I have seen comes from @HopkinsMedicine team
Risk of mets at 5 years is only 26% for #PSA DT 6-9 months. Significantly lower risk than DT 3-6 mos or DT under 3 mos
ascopubs.org/doi/10.1200/...
Best data I have seen comes from @HopkinsMedicine team
Risk of mets at 5 years is only 26% for #PSA DT 6-9 months. Significantly lower risk than DT 3-6 mos or DT under 3 mos
ascopubs.org/doi/10.1200/...
November 27, 2024 at 12:58 PM
Since #EMBARK data there is a need to define high risk #BCR #ProstateCancer
Best data I have seen comes from @HopkinsMedicine team
Risk of mets at 5 years is only 26% for #PSA DT 6-9 months. Significantly lower risk than DT 3-6 mos or DT under 3 mos
ascopubs.org/doi/10.1200/...
Best data I have seen comes from @HopkinsMedicine team
Risk of mets at 5 years is only 26% for #PSA DT 6-9 months. Significantly lower risk than DT 3-6 mos or DT under 3 mos
ascopubs.org/doi/10.1200/...
Reposted by Oncodoc
Review: The present and future of bispecific antibodies for cancer therapy
The present and future of bispecific antibodies for cancer therapy - Nature Reviews Drug Discovery
Bispecific antibodies (bsAbs) can mediate therapeutic effects beyond those of natural monospecific antibodies. This Review provides an overview of recent developments in the field of bsAbs for cancer ...
www.nature.com
November 27, 2024 at 3:46 AM
Review: The present and future of bispecific antibodies for cancer therapy
Reposted by Oncodoc
Elucidating acquired PARP inh resistance
sciencedirect.com/science/arti...
Highlights emergence of resistance in met CR #ProstateCancer tx w/ PARP inh💊, particularly in BRCA2 & PALB2 mutations🧬
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@achoud72.bsky.social
@yukselurun.bsky.social
sciencedirect.com/science/arti...
Highlights emergence of resistance in met CR #ProstateCancer tx w/ PARP inh💊, particularly in BRCA2 & PALB2 mutations🧬
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@achoud72.bsky.social
@yukselurun.bsky.social
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
PARP inhibition (PARPi) has anti-tumor activity against castration-resistant prostate cancer (CRPC) with homologous recombination repair (HRR) defects…
sciencedirect.com
November 26, 2024 at 6:04 PM
Elucidating acquired PARP inh resistance
sciencedirect.com/science/arti...
Highlights emergence of resistance in met CR #ProstateCancer tx w/ PARP inh💊, particularly in BRCA2 & PALB2 mutations🧬
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@achoud72.bsky.social
@yukselurun.bsky.social
sciencedirect.com/science/arti...
Highlights emergence of resistance in met CR #ProstateCancer tx w/ PARP inh💊, particularly in BRCA2 & PALB2 mutations🧬
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@achoud72.bsky.social
@yukselurun.bsky.social
Reposted by Oncodoc
How the Andromeda galaxy would look from Earth if it were brighter
November 19, 2024 at 8:48 AM
How the Andromeda galaxy would look from Earth if it were brighter